Search clinical trials for: Neoadjuvant tamoxifen goserelin (premenopausal women)

Total 41 results

Haukeland University Hospital
Pfizer; AstraZeneca; Helse Vest

Active, not recruiting

PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial (PETREMAC)

Breast Cancer

Norway
Ruijin Hospital

Terminated

Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients (COMPETE)

Breast Cancer

China
University of Copenhagen

Completed

Evaluation of the Association Between the Menstrual Cycle and Weight Loss in Healthy, Overweight Premenopausal Women (MENSTRALEAN)

Obesity

Denmark
Korean Breast Cancer Study Group

Unknown

Evaluating the Role of the Addition of Ovarian Function Suppression (OFS) to Tamoxifen in Young Women (ASTRRA)

Breast Cancer

Korea, Republic of
NCIC Clinical Trials Group

Terminated

Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate Cancer (DART)

Prostate Cancer

Canada
Cancer Research UK

Unknown

Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer

Breast Cancer

United Kingdom, Belgium
Zhejiang Cancer Hospital

Completed

Zoladex Plus Tamoxifen in Breast Cancer

Ultrasonography | Lipemia | Endometrium | Mammography | Estrogen

China
Austrian Breast & Colorectal Cancer Study Group
AstraZeneca; Novartis Pharmaceuticals

Completed

Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid

Breast Cancer

Austria, Germany
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Completed

TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer

Breast Cancer | Breast Cancer - Female | Breast Cancer - Male

United States
Anglo Celtic Cooperative Oncology Group

Completed

Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer

Breast Cancer | Infertility | Menopausal Symptoms

United Kingdom
Thomas Hatschek

Active, not recruiting

Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors (PREDIX LumA)

Early-Stage Breast Carcinoma | Hormone Receptor Positive Tumor

Sweden
National Cancer Institute (NCI)

Terminated

Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer

Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Positive | HER2/Neu Negative

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Neoadjuvant Hormones + Docetaxel in Node-Positive Prostate Cancer

Prostate Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
Sanofi

Terminated

Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

Prostate Cancer

United States
Virginia Commonwealth University
National Cancer Institute (NCI)

Completed

Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Ductal Breast Carcinoma in Situ | Lobular Breast Carcinoma in Situ

United States, Canada
Technical University of Munich

Unknown

Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery

Breast Cancer

Germany
Cedars-Sinai Medical Center

Unknown

Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast

Breast Cancer

United States
NCIC Clinical Trials Group

Completed

Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer

Prostate Cancer

Canada
Thomas Hatschek

Active, not recruiting

Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases (PREDIX LumB)

Early-Stage Breast Carcinoma | Estrogen Receptor Positive Tumor

Sweden
Novartis Pharmaceuticals

Completed

A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Japan, Hong Kong, Singapore
AstraZeneca

Completed

Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment

Breast Cancer

Japan
University of California, San Francisco
Novartis

Completed

Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ

Breast Cancer

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (e3)

Breast Cancer

United States, Puerto Rico
German Breast Group
Pfizer

Completed

Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients (MALE)

Male Breast Cancer

Germany
UNICANCER

Terminated

Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer

Breast Cancer

France
Washington University School of Medicine
Genomic Health®, Inc.

Recruiting

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

Breast Cancer | Breast Neoplasms | Cancer of Breast | Cancer of the Breast

United States
Ludwig-Maximilians - University of Munich

Completed

Combination Chemotherapy in Treating Women With Breast Cancer

Breast Cancer

Germany
Scottish Cancer Therapy Network

Completed

Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer

Breast Cancer

United Kingdom
Blokhin's Russian Cancer Research Center

Recruiting

Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia (NEMO)

Breast Cancer | Neoadjuvant Endocrine Therapy

Russian Federation
National Cancer Center, Japan
Pfizer; Korean Cancer Study Group

Active, not recruiting

PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY (PATHWAY)

Breast Neoplasms

Korea, Republic of, Singapore, Japan, Taiwan
Grant Dorsey, M.D, Ph.D.
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Reducing the Burden of Malaria in HIV-uninfected Pregnant Women and Infants (PROMOTE-BC1)

Malaria

Uganda
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (MONALEESA-7)

Advanced Metastatic Breast Cancer

Canada, Italy, Hungary, Taiwan, Turkey, Belgium, Germany, Spain, United States, Singapore, Australia, Korea, Republic of, Hong Kong, Thailand, Lebanon, Bulgaria, France, Russian Federation, Argentina, Brazil, Malaysia, Portugal, Col... and more
Novartis Pharmaceuticals

Recruiting

Roll-over Study to Allow Continued Access to Ribociclib

Metastatic Breast Cancer

United States, Lebanon, Hong Kong, Turkey, Vietnam, Brazil, Italy, Korea, Republic of, Poland, Taiwan, Singapore, Japan, South Africa, Spain, Costa Rica, Greece, Portugal, Argentina, Mexico
First Affiliated Hospital, Sun Yat-Sen University

Recruiting

Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women (ASPAIT)

Breast Cancer

China
Institute of Cancer Research, United Kingdom
Scottish Cancer Therapy Network; Cancer Research Campaign Clinical Trials Centre and other collaborators

Completed

Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer

Breast Cancer

United Kingdom
Zhiyong Yu

Unknown

Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer

Breast Cancer | Chemotherapy | Endocrine Breast Diseases
Austrian Breast & Colorectal Cancer Study Group
AstraZeneca

Completed

Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients

Early-stage Breast Cancer
University of Chicago

Not yet recruiting

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

Breast Cancer | HER2-positive Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

United States
University of Nebraska
National Cancer Institute (NCI)

Completed

Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)

Breast Cancer

United States
National Institute of Oncology, Hungary

Not yet recruiting

Neoadjuvant Treatment of Breast Cancer

Breast Cancer

Hungary
Palleos Healthcare GmbH
Roche Pharma AG; Cankado GmbH; WSG WOMEN´S HEALTHCARE STUDY GROUP

Completed

Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients (TP-II)

Breast Neoplasms

Germany

Search clinical trials for: Neoadjuvant tamoxifen goserelin (premenopausal women)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations